NNZ-2591 for the Treatment of Angelman Syndrome: Results From a Phase 2 Open-Label StudyLikeFollowShareShare your feedbackQuestions (0)Post questionYour question will be sent privately to Neuren Pharmaceuticals. The company may choose to make this question public.Start the conversationAsk Neuren Pharmaceuticals a question about this update.Discover
